THE 6th EXPERT MEETING ON THERAPEUTIC MSCs FOR IMMUNE MODULATION
REGENSBURG, GERMANY. OCTOBER 27 – 28, 2016

Thursday 27 October

Meeting Venue
Brücksaal im Historischen Salzstadl
(directly at the “Steinerne Brücke”)
Weiße-Lamm-Gasse 1, 93047 Regensburg
Phone: +49 (0)941 5071415

The “Salzstadel” (salt barn) dates from 1616 and is a reminder of the salt trade from which Regensburg has housed restaurants, several shops and even rentable rooms. The building now also houses the Regensburg UNESCO World Heritage visitor center.

8:30 – onwards registration & view company exhibitions
8:55 MiSOT opening address.
Marc Dahlke, Regensburg, Germany.

Session 1. Mechanistic insights into MSC therapies

09:15 What do we really know about MSC therapy?
Martin Hoogduijn, Rotterdam, The Netherlands.

09:45 Molecular pathways affected by MSC in a model of non-alcoholic steatohepatitis.
Bruno Christ, Leipzig, Germany

10:00 How mechanistic studies on MSCs inform design of human clinical trials - The fitness paradigm.
Jacques Galipeau, Madison, Wisconsin, USA.

10:30 Inflammatory conditions dictate the immunomodulatory effect of MSC on B cell function.
Marcella Franquesa, Badalona, Spain.

10:45 Catherine Verfaillie, Leuven, Belgium.

11:15 Coffee
Session 2. MSC for solid organ transplantation

11:35  3D MSCs constructs in models of chronic liver failure.  
      Murat Shagidulin, Moscow, Russia.

11:50  What do we learn from MSC treatment in clinical kidney transplantation?  
      Marlies Reinders, Leiden, The Netherlands.

12:20  MSC after deceased donor liver transplantation: a phase I/II study of the University of Liege.  
      Olivier Detry, Liège, Belgium.

12:50  Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation.  
      Steffen Hartleif, Tübingen, Germany.

13:05  Mesenchymal stromal cells to promote tolerance in kidney transplantation: from mice to men and back.  
      Giuseppe Remuzzi, Bergamo, Italy.

13:35  Lunch

Session 3. MSC for inflammatory and immunological disorders

14:35  Cellular Immunotherapy for Severe Sepsis: the CISS Trial.  
      Claudia Dos Santos, Ottawa, Canada.


15:35  MSC: a new route in the road map of therapies for inflammatory bowel diseases.  
      Rachele Ciccocioppo, Pavia, Italy.

16:05  UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells.  
      Marta Monguíó-Tortajada, Badalona, Spain.

16:20  Harnessing Mesenchymal Stromal Cells for Immune Modulatory Treatment.  
      Wim Fibbe, Leiden, The Netherlands.

19:00  Networking Dinner

Haus Heuport
Domplatz 7, 93047 Regensburg
Phone: +49 (0)941 599 9297
www.heuport.de

MiSOT 2016 is generously supported by
Friday 28 October

Session 4. Corporate Session: Bringing MSC-based technologies to market

9:00  Generation of polyclonal Tregs with superior expansion potential and enhanced Th1 suppression via MAPC co-culture.
Samantha Stubblefield, Regenerative Medicine Scientist, Athersys Inc.

9:20  From CD362 to ORBCEL: the rapid development of an allogeneic stromal cell immunotherapy
Stephen Elliman, CSO, Orbsen Therapeutics.

9:40  Case Study review on large scale manufacturing of MSCs.
Amel Tounsi, Project & Development Manager, MaSTherCell.

9:00  Potential use of adipose mesenchymal stem cells in sepsis: The SEPCELL trial
Eleuterio Lombardo, Scientific Director, TiGenix SAU.

10:00  Addressing Challenges in ATMP Manufacture.
Layka Abbasi, Cell processing Specialist, Terumo BCT.

10:40  Alpha 1 anti-trypsin expressing mesenchymal stem cells suppress type 1 diabetes development in NOD mice
Felix Hermann, Head of Preclinical Development, apceth GmbH.

11:00  Coffee

Session 5. MSC for tissue protection

11:15  Impact of timing administration of mesenchymal stromal cells following renal ischemia/reperfusion in rats.
Pauline Erpicum, Liège, Belgium.

11:45  MSC in immune-mediated liver disease.
Philip Newsome, Birmingham, UK.

12:15  Normothermic Organ Perfusion: Opportunities and Challenges.
Rutger Ploeg, Oxford, UK.

12:45  Administering MSCs to an isolated organ prior to transplantation.
Cyril Moers, Groningen, The Netherlands.

13:15 – Lunch plus closing remarks